On-Demand Event

Differentiating Basal Insulin Analogues by Hypoglycemia

Original air date:
Sunday, August 1, 2021

Running time: 15 minutes



Ronald GoldenbergMD; Jeffrey Habert, MD

In this episode, we are pleased to welcome back Ronald Goldenberg, consultant Endocrinologist at LMC Diabetes & Endocrinology and Jeffrey Habert, family physician and assistant professor at University of Toronto. How have basal insulin analogues been improving over the years? They describe the clinical benefits of newer basal insulin analogues including flexible dosing options, longer duration of action and minimizing the effect of hypoglycemia.

The views information and opinions expressed in this podcast are solely those of the individuals involved and do not represent those of Novo Nordisk.

This podcast does not constitute medical advice and is only meant to educate and inform the listener.

This podcast has been supported by educational funding from Novo Nordisk.

Language: English